The clinical use of the high doses of SLM determined clinically safe is now under evaluation in sequential combination with axitinib, a VEGFR inhibitor, in heavily pretreated patients with advanced ccRCC. The gene discussed is KDR; the disease is nonpapillary renal cell carcinoma.